Similar articles

• [Therapeutic indications for sotalol 160 mg].

  Ginestes J. Ginestes J. Ann Cardiol Angeiol (Paris). 1985 Jan;34(1):45-52. Ann Cardiol Angeiol (Paris). 1985. PMID: 2579609 French. No abstract available.
• On the use of a dynamic approach to the estimation of dissociation constants for reversible competitive antagonists.

  Amidon GL, Buckner CK. Amidon GL, et al. J Pharmacol Exp Ther. 1981 Feb;216(2):352-6. J Pharmacol Exp Ther. 1981. PMID: 6257889
• [beta receptors. Contrast between the acute and prolonged effects of beta blockers].

  Williams EM. Williams EM. Actual Pharmacol (Paris). 1978;30:187-202. Actual Pharmacol (Paris). 1978. PMID: 28639 Review. French. No abstract available.
• d-sotalol reduces heart rate in vivo through a beta-adrenergic receptor-independent mechanism.

  Yasuda SU, Barbey JT, Funck-Brentano C, Wellstein A, Woosley RL. Yasuda SU, et al. Clin Pharmacol Ther. 1993 Apr;53(4):436-42. doi: 10.1038/clpt.1993.48. Clin Pharmacol Ther. 1993. PMID: 8386603 Clinical Trial.
• [Clinical pharmacology of anti-arrhythmia agents. III. Drugs blocking beta adrenergic receptors].

  Witkowska M. Witkowska M. Kardiol Pol. 1982;25(2):147-61. Kardiol Pol. 1982. PMID: 6125621 Review. Polish. No abstract available.